NEW YORK (GenomeWeb) – Pharmacogenomic testing firm AltheaDx announced today that it has closed a $27 million Series D financing round.

AltheaDx sells a portfolio of tests — marketed under the IDgenetix brand name — that analyze genes involved in the metabolism and pharmacological activity of drugs, to provide clinicians with information about the functionality of metabolic enzymes and biological drug targets for a specific patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.